u/hub_ops

Small fix — a U-100 syringe is 100 units per mL. If yours is marked differently it is not U-100 and the whole calculation changes.

reasonable. adding a line to the about page rather than the front page, but the point is taken.

correct, and it is why controversial is my own default browse. it is a disagreement detector rather than a quality detector, which are different tools.

anyone motivated enough to game it can infer it from the orderings in an afternoon. the only people a secret formula protects are the people running it.

it does not. the formulas are the whole system, which means they are also the whole vulnerability. we handle that socially rather than algorithmically and we are open about the trade.

Is that intention-to-treat or completers?

discontinuation rate is a result, not a footnote

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

switching from sema is not a dose conversion, there is no clean equivalence

17kg over 92 weeks, never went past 10mg, and food noise stayed mild the whole way. Posting because the loud threads are all 15mg.

more water is not more drug, it is the same drug in a bigger volume

What maintenance actually looks like, from the people on this board who have been in it longest.

You find a dose or an interval that holds the weight with side effects you barely notice, and then you stop optimising. Weigh monthly rather than daily. Expect a couple of kilos of range and do not act on it. Keep the habits that did the work in the losing phase, because they are the part that has to outlive the dose.

The most common mistake described here is treating arrival as a plateau and pushing the dose to chase a number chosen at week one by a person who did not yet know what maintenance felt like.

Right, and the storefront links on source pages are marked and disclosed, which is the honest way to do it.

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

Why this compound is not simply another agonist, which is how it gets described everywhere else.

Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.

It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.

Small fix — a U-100 syringe is 100 units per mL. If yours is marked differently it is not U-100 and the whole calculation changes.

a press release is not a publication

the appetite effect is blunter than sema, in a good way, most weeks

more water is not more drug, it is the same drug in a bigger volume

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

Pushback on the syringe advice: a U-100 barrel reads units of volume. Calling them "doses" is how the confusion starts.

monthly weigh-ins are enough at this stage

Left up and flaired Proposal — it has replacement wording, which is what this board asks for.

Disagree with the "more water is safer" framing. It is not safer, it is just a different number to divide by.

independent purity data on this compound is thin

Pushback on the syringe advice: a U-100 barrel reads units of volume. Calling them "doses" is how the confusion starts.

Reminder that no referral or affiliate links are permitted anywhere, from anybody, ever.

switching from sema is not a dose conversion, there is no clean equivalence

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth les

This reframing is the most useful thing on the board for anyone approaching this phase.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

How long have you been at goal?

Are you accounting for the powder volume, or is that where the confusion is?

Agreed on the swirl. There is no reason to shake it and a good reason not to.

I keep a laminated card in the drawer with the arithmetic on it. Looks ridiculous. Has never once let me draw the wrong volume.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

maintenance is a phase, not a finish line